With a history that can be traced all the way back to 1849, Pfizer is a mega-cap pharmaceutical and biotechnology company. The pandemic made it even more well-known globally.
Over 3.6 billion Pfizer-BioNTech COVID-19 vaccines have been shipped to 180 countries worldwide. Meanwhile, Pfizer is also the developer of Paxlovid, an oral antiviral pill used to treat COVID-19.
The company reported strong results this earnings season. For Q2, Pfizer generated $27.7 billion of revenue, representing a 47% increase year-over-year. Adjusted earnings per share came in at $2.04, up 92% from the year-ago period.
The stock, however, is not immune to the market sell-off in 2022. Year-to-date, Pfizer shares have slipped 12%.
JPMorgan analyst Chris Schott has a ‘neutral’ rating on Pfizer and a price target of $57 — roughly 15% above where the stock sits today.
Gilead Sciences (GILD)
Gilead Sciences is another biopharmaceutical company that made headlines during the pandemic. It is the developer of Veklury (remdesivir), the first antiviral drug approved by the FDA for the treatment of COVID-19 requiring hospitalization.
The company reported Q2 earnings on Tuesday. For the quarter, revenue edged up 1% year-over-year to $6.3 billion. Adjusted earnings per share declined 13% year over year to $1.58.
While these numbers don’t look impressive on their own, they smashed Wall Street’s expectations. On average, analysts expected Gilead to report earnings of $1.52 per share on $5.86 billion of revenue for the quarter.
Management also boosted their guidance. For full-year 2022, they expect the company to earn $24.5 billion to $25 billion in total product sales, up from their previous guidance range of $23.8 billion to $24.3 billion.
The stock shot up 4.6% on Wednesday. However, it’s still down 14% year to date.
Piper Sandler analyst Do Kim recently reiterated a ‘neutral’ rating on Gilead while raising the price target from $69 to $71. Considering that Gilead trades at $62.27 today, the price target implies a potential upside of 14%.
Abbott Laboratories (ABT)
Abbott Laboratories is a healthcare company that specializes in medical devices, diagnostics, nutrition products, and branded generic medicines.
Like the other two companies, Abbott hasn’t been a hot ticker. Its shares have fallen a painful 21% in 2022.
But the company is solidly-positioned for another wave of COVID-19 – it makes COVID-19 testing kits.
According to the latest earnings report, COVID-19 testing-related sales amounted to $2.3 billion for Abbott in Q2 of 2022.
Sales totaled $11.3 billion for the quarter, representing a 10.1% increase year over year. Adjusted earnings per share grew 22.2% from a year ago to $1.43.
Management expects the company to earn $6.1 billion in COVID-19 testing-related sales in full-year 2022.
Citi analyst Joanne Wuensch has a ‘buy’ rating on Abbott and a price target of $123 — around 12% above the current levels.
Fine art as an investment
Stocks can be volatile, cryptos make big swings to either side, and even gold is not immune to the market’s ups and downs.
That’s why if you are looking for the ultimate hedge, it could be worthwhile to check out a real, but overlooked asset: fine art.
Contemporary artwork has outperformed the S&P 500 by a commanding 174% over the past 25 years, according to the Citi Global Art Market chart.
And it’s becoming a popular way to diversify because it’s a real physical asset with little correlation to the stock market.
On a scale of -1 to +1, with 0 representing no link at all, Citi found the correlation between contemporary art and the S&P 500 was just 0.12 during the past 25 years.
Earlier this year, Bank of America investment chief Michael Harnett singled out artwork as a sharp way to outperform over the next decade — due largely to the asset’s track record as an inflation hedge.
Investing in art by the likes of Banksy and Andy Warhol used to be an option only for the ultrarich. But with a new investing platform, you can invest in iconic artworks just like Jeff Bezos and Bill Gates do.